Account Info
Log Out
English
Back
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh Refresh
Loading
History record delete
    Quotes All >
      News All >
        Log in to access Online Inquiry
        Watchlist
        Loading...
        US Stock MarketDetailed Quotes
        NKTX Nkarta Watchlist
        4.750 +0.160+3.49% Close 06/02 16:00 ET
        5.150+0.400+8.42% Post 19:58 ET
        4.840High4.600Low170.01KVolume
        Post-Market
        • 5D
        • 1D
        • 1W
        • 1M
        • 1Q
        • 1Y

        Company

        Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

        Revenue Breakdown

        Business Unit:USD
        NameYOYOperating income%
        Single segment--115.39K100.00%
        Paper Trade Start
        Symbol
        Direction
        Buy
        Sell
        Types
        LMT Order
        Price
        QTY
        Amount
        --